Page last updated: 2024-12-05

norcamphor

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Norcamphor, also known as bicyclo[2.2.1]heptan-2-one, is a bicyclic ketone that has garnered significant interest in organic chemistry and medicinal chemistry. It serves as a versatile building block for the synthesis of various complex organic molecules. Its unique structure, featuring a bridged bicyclic system, offers opportunities for the development of novel pharmaceuticals and materials. Researchers are particularly drawn to norcamphor due to its ability to participate in various reactions, including Diels-Alder cycloadditions and ring-opening metathesis. The strained nature of its ring system contributes to its reactivity. Furthermore, norcamphor has been investigated for its potential biological activities. For instance, studies have explored its role in modulating enzyme activity and its potential as an anti-inflammatory agent. The exploration of norcamphor's chemical and biological properties continues to drive research efforts in various fields.'

norcamphor: RN given refers to cpd without isomeric desination [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10345
CHEMBL ID361682
SCHEMBL ID83478
MeSH IDM0155188

Synonyms (44)

Synonym
LS-13291
NCIOPEN2_001420
2,5-methanocyclohexanone
nsc 66537
8,9,10-trinorbornan-2-one
ai3-51353
einecs 207-846-1
bicyclo(2.2.1)heptan-2-one
2-oxonorbornane
2-norbornanone
norbornan-2-one
nsc66537
nsc-66537
norcampher
bicyclo[2.2.1]heptan-2-one
norcamphor
nsc92359
nsc-92359
497-38-1
CHEMBL361682
2-norcamphor
N0511
bicyclo[2.2.1]-2-heptanone
AKOS000121061
FT-0689926
SCHEMBL83478
AKOS022146289
(-)-2-norbornanone
norbornanone
(+)-2-norbornanone
bicyclo(2.2.1)-2-heptanone
bicyclo[2.2.1]heptane-2-one
F0001-1297
mfcd00074823
rac-norcamphor
CCG-358829
Q7050470
AMY10402
EN300-15383
DTXSID50883406
A871731
SY049592
PB42918
CS-0072123
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID249150Lethal concentration required to kill 50% Caki-1 cells of the human renal carcinoma with non-mutant wt p532004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Identification and structure-activity relationship studies of 3-methylene-2-norbornanone as potent anti-proliferative agents presumably working through p53 mediated apoptosis.
AID249153Lethal concentration required to kill 50% Ramos RA1 cells of the human lymphocyte with a mutation at Asp 2542004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Identification and structure-activity relationship studies of 3-methylene-2-norbornanone as potent anti-proliferative agents presumably working through p53 mediated apoptosis.
AID252829Fold selectivity expressed as ratio of LC50 for Caki cells with non-mutant p53 to LC50 for Ramos RA1 cells with a mutation at Asp 2542004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Identification and structure-activity relationship studies of 3-methylene-2-norbornanone as potent anti-proliferative agents presumably working through p53 mediated apoptosis.
AID249152Lethal concentration required to kill 50% C33A cells of the human cervical cells with a mutation at Cys 2732004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Identification and structure-activity relationship studies of 3-methylene-2-norbornanone as potent anti-proliferative agents presumably working through p53 mediated apoptosis.
AID252828Fold selectivity expressed as ratio of LC50 for Caki cells with non-mutant p53 to LC50 for C33A cells with a mutation at Cys 2732004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Identification and structure-activity relationship studies of 3-methylene-2-norbornanone as potent anti-proliferative agents presumably working through p53 mediated apoptosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (15.79)18.7374
1990's4 (21.05)18.2507
2000's7 (36.84)29.6817
2010's3 (15.79)24.3611
2020's2 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.09 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]